# Molecular Mechanisms and Treatment Strategies of ALK‐Positive Lung Cancer: A Beginner's Guide for Patients, Their Families and Carers

## TL;DR

This beginner's guide explains the molecular basis and treatment options for ALK-positive lung cancer in simple terms for patients and their families.

## Contribution

The paper provides an accessible, patient-friendly overview of ALK-positive lung cancer mechanisms and therapies.

## Key findings

- ALK-positive lung cancer involves the EML4-ALK hybrid protein, which drives uncontrolled cell growth.
- Tyrosine kinase inhibitors (TKIs) block EML4-ALK activity by competing with ATP for binding to the protein's active site.
- The review outlines current therapeutic strategies targeting ALK-positive lung cancer.

## Abstract

This review has been written with the intention of explaining to the patients with ALK‐positive lung cancer, and to their families, friends, carers and medical teams, in simple terms, the fundamentals, and the current state of knowledge of this particular type of cancer. The review begins with basic facts about lung anatomy and lung cancer, then explains general principles of how cell proliferation is regulated at the molecular level. The coverage of the molecular events underlying the development of ALK‐positive lung cancer and principles of targeted therapies then follows. The review concludes with an analysis of various therapeutic approaches to treat ALK‐positive lung cancer. The Supporting Information section contains additional advanced information illustrating specific points of interest.

Inhibition of EML‐ALK function by TKI. In cells, not treated with TKI, ATP binding occurs in the active site (pocket) of the hybrid protein, leading to its activation and functional effects. Introduction of a TKI leads to TKI compete with ATP for binding to the active site. Keys: ALK ‐ Anaplastic Lymphoma Kinase; EML4 ‐ Echinoderm microtubule‐associated protein‐like; ATP ‐ Adenosine triphosphate; TK ‐ Tyrosine Kinase; TKI ‐ Tyrosine Kinase Inhibitor.